Novel immunotherapies in lymphoid malignancies

Nature Reviews Clinical Oncology

Volumn 13, Issue 1, 2016, Pages 25-40

  Batlevi, Connie Lee ^a   Matsuki, Eri ^a   Brentjens, Renier J ^a   Younes, Anas ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BLINATUMOMAB; BRENTUXIMAB VEDOTIN; CARMUSTINE; CHECKPOINT KINASE INHIBITOR; CHIMERIC ANTIGEN RECEPTOR; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IMMUNOGLOBULIN; INTERLEUKIN 2; IPILIMUMAB; MELPHALAN; NIVOLUMAB; PEMBROLIZUMAB; PENTOSTATIN; PIDILIZUMAB; PREDNISONE; PROGRAMMED DEATH 1 LIGAND 1; RITUXIMAB; STEROID; TOCILIZUMAB; URELUMAB; VINCRISTINE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ANTIBODY COMBINING SITE; ANTIGEN EXPRESSION; APHASIA; APLASIA; ATAXIA; AUTOIMMUNITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN DISEASE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CELL INFILTRATION; CELL THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM INFECTION; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOKINE RELEASE SYNDROME; CYTOTOXIC T LYMPHOCYTE; DISORIENTATION; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTROPORATION; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FOLLICULAR LYMPHOMA; GENETIC ENGINEERING; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOLOGIC MALIGNANCY; HEPATITIS; HODGKIN DISEASE; HUMAN; HYPOKALEMIA; HYPOPHYSITIS; HYPOTENSION; HYPOTHYROIDISM; HYPOXIA; IMMUNOGLOBULIN DEFICIENCY; IMMUNOPATHOLOGY; INFECTION; JOINT SWELLING; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LEUKEMIA RELAPSE; LEUKOPENIA; LUNG DISEASE; LYMPHATIC LEUKEMIA; LYMPHATIC SYSTEM DISEASE; LYMPHOCYTE DEPLETION; LYMPHOCYTOSIS; LYMPHOPROLIFERATIVE DISEASE; MACROPHAGE ACTIVATION SYNDROME; MAXIMUM TOLERATED DOSE; MENTAL DISEASE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MYELOID LEUKEMIA; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PNEUMONIA; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RECURRENCE FREE SURVIVAL; RESPIRATORY DISTRESS SYNDROME; REVIEW; SEIZURE; SEPSIS; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TACHYCARDIA; THROMBOCYTOPENIA; THYROIDITIS; TRANSPOSON; TREATMENT FAILURE; TREMOR; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT; ADULT; IMMUNOLOGY; IMMUNOTHERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; TREATMENT OUTCOME;

ADULT; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RITUXIMAB; TREATMENT OUTCOME;

EID: 84951905956     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.187     Document Type: Review

References (172)

1. Horowitz, M. et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75, 555-562 (1990).
2. Maloney, D. G. et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15, 3266-3274 (1997).
3. Maloney, D. G. et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90, 2188-2195 (1997).
4. Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235-242 (2002).
5. Doubrovina, E. et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 119, 2644-2656 (2012).
6. Chapuis, A. G. et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-Transplant patients. Sci. Transl. Med. 5, 174ra27 (2013).
7. Rooney, C. M. et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549-1555 (1998).
8. Heslop, H. E. et al. Long-Term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115, 925-935 (2010).
9. Bollard, C. M. et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J. Clin. Oncol. 32, 798-808 (2014).
10. Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90, 720-724 (1993).
11. Annenkov, A. E., Moyes, S. P., Eshhar, Z., Mageed, R. A. & Chernajovsky, Y. Loss of original antigenic specificity in T cell hybridomas transduced with a chimeric receptor containing single-chain Fv of an anti-collagen antibody and FcεRI-signaling γ subunit. J. Immunol. 161, 6604-6613 (1998).
12. Haynes, N. M. et al. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-ζ vs FcεRI-γ. J. Immunol. 166, 182-187 (2001).
13. Gross, G., Waks, T. & Eshhar, Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-Type specificity. Proc. Natl Acad. Sci. USA 86, 10024-10028 (1989).
14. Bird, R. E. et al. Single-chain antigen-binding proteins. Science 242, 423-426 (1988).
15. Huston, J. S. et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl Acad. Sci. USA 85, 5879-5883 (1988).
16. Orlandi, R., Gussow, D. H., Jones, P. T. & Winter, G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl Acad. Sci. USA 86, 3833-3837 (1989).
17. Hollyman, D. et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J. Immunother. 32, 169-180 (2009).
18. Lee, J., Sadelain, M. & Brentjens, R. Retroviral transduction of murine primary T lymphocytes. Methods Mol. Biol. 506, 83-96 (2009).
19. Quintas-Cardama, A. et al. Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. Hum. Gene Ther. 18, 1253-1260 (2007).
20. Brentjens, R. J. et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 13, 5426-5435 (2007).
21. Brentjens, R. J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9, 279-286 (2003).
22. Huang, X. et al. Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol. Ther. 16, 580-589 (2008).
23. Kochenderfer, J. N. et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J. Immunother. 32, 689-702 (2009).
24. Savoldo, B. et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822-1826 (2011).
25. Wang, X. et al. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J. Immunother. 35, 689-701 (2012).
26. Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453-1464 (2009).
27. Terakura, S. et al. Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood 119, 72-82 (2012).
28. Zola, H. et al. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol. Cell Biol. 69, 411-422 (1991).
29. Bejcek, B. E. et al. Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen. Cancer Res. 55, 2346-2351 (1995).
30. Nicholson, I. C. et al. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol. Immunol. 34, 1157-1165 (1997).
31. Imai, C. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18, 676-684 (2004).
32. Till, B. G. et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112, 2261-2271 (2008).
33. Jensen, M. C. et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol. Blood Marrow Transplant. 16, 1245-1256 (2010).
34. Wang, J. et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum. Gene Ther. 18, 712-725 (2007).
35. Maher, J., Brentjens, R. J., Gunset, G., Riviere, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor. Nat. Biotechnol. 20, 70-75 (2002).
36. Hombach, A. A., Rappl, G. & Abken, H. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation". Mol. Ther. 21, 2268-2277 (2013).
37. Carpenito, C. et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 106, 3360-3365 (2009).
38. Zhong, X. S., Matsushita, M., Plotkin, J., Riviere, I. & Sadelain, M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 18, 413-420 (2010).
39. Tammana, S. et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum. Gene Ther. 21, 75-86 (2010).
40. Pegram, H. J., Park, J. H. & Brentjens, R. J. CD28z CARs and armored CARs. Cancer J. 20, 127-133 (2014).
41. Jones, B. S., Lamb, L. S., Goldman, F. & Di Stasi, A. Improving the safety of cell therapy products by suicide gene transfer. Front. Pharmacol. 5, 254 (2014).
42. Di Stasi, A. et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113, 6392-6402 (2009).
43. Kershaw, M. H. et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther. 13, 1971-1980 (2002).
44. Brentjens, R. J. et al. Safety and persistence of adoptively transferred autologous CD19-Targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817-4828 (2011).
45. Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
46. Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099-4102 (2010).
47. Wang, X. & Riviere, I. Manufacture of tumor-And virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther. 22, 85-94 (2015).
48. Brentjens, R. J. et al. CD19-Targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).
49. Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).
50. Park, J. H. et al. CD19-Targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL [abstract]. Blood 124, a382 (2014).
51. Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014).
52. Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet 385, 517-528 (2015).
53. Fielding, A. K. et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109, 944-950 (2007).
54. Gökbuget, N. et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120, 2032-2041 (2012).
55. Kantarjian, H. M. et al. Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk. Lymphoma 51, 475-480 (2010).
56. Curran, K. J. et al. Validation of donor derived virus specific T-lymphocytes genetically modified to target the CD19 antigen for the treatment of relapsed Leukemia. Mol. Ther. 19, S90 (2011).
57. Kochenderfer, J. N. et al. Donor-derived CD19-Targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122, 4129-4139 (2013).
58. Park, J. H. et al. Impact of the conditioning chemotherapy on outcomes in adoptive T cell therapy: results from a phase I clinical trial of autologous CD19-Targeted T cells for patients with relapsed CLL [abstract]. Blood 120, a1797 (2012).
59. Park, J. H. et al. Phase I trial of autologous CD19-Targeted CAR-modified T cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL [abstract]. J. Clin. Oncol. 32 (5s Suppl.), a7020 (2014).
60. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
61. Porter, D. L. et al. Chimeric antigen receptor modified t cells directed against CD19 (CTL019 cells) have long-Term persistence and induce durable responses in relapsed, refractory CLL [abstract]. Blood 122, a4162 (2013).
62. Porter, D. L. et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL [abstract]. Blood 124, a1982 (2014).
63. Kochenderfer, J. N. et al. B-cell depletion and remissions of malignancy along with cytokine-Associated toxicity in a clinical trial of anti-CD19 chimeric-Antigen-receptor-Transduced T cells. Blood 119, 2709-2720 (2012).
64. Kochenderfer, J. N. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540-549 (2015).
65. Kochenderfer, J. N. et al. Anti-CD19 CAR T cells administered after low-dose chemotherapy can induce remissions of chemotherapy-refractory diffuse large B-cell lymphoma [abstract]. Blood 124, a550 (2014).
66. Schuster, S. J. et al. Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas [abstract]. Blood 124, a3087 (2014).
67. Sauter, C. S. et al. Interim safety analysis: A phase I trial of high dose therapy and autologous stem cell transplantation followed by infusion of chimeric antigen receptor modified T-cells (19-28z CAR-T) directed against CD19+ B-cells for relapsed and refractory aggressive B cell non-Hodgkin lymphoma (B-NHL) [abstract]. Blood 124, a677 (2014).
68. Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188-195 (2014).
69. Maude, S. L., Barrett, D., Teachey, D. T. & Grupp, S. A. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 20, 119-122 (2014).
70. Ramos, C. A., Savoldo, B. & Dotti, G. CD19-CAR trials. Cancer J. 20, 112-118 (2014).
71. Maude, S. L., Teachey, D. T., Porter, D. L. & Grupp, S. A. CD19-Targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125, 4017-4023 (2015).
72. Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 (2013).
73. Turtle, C. J. et al. Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition [abstract]. J. Clin. Oncol. 33 (Suppl.), a3006 (2015).
74. Wang, X. et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255-1263 (2011).
75. Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673-1683 (2011).
76. Giordano Attianese, G. M. et al. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood 117, 4736-4745 (2011).
77. Berger, C. et al. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol. Res. 3, 206-216 (2015).
78. Haso, W. et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121, 1165-1174 (2013).
79. Vera, J. et al. T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 108, 3890-3897 (2006).
80. Savoldo, B. et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 110, 2620-2630 (2007).
81. Ruella, M. et al. Novel chimeric antigen receptor T cells for the treatment of Hodgkin lymphoma [abstract]. Blood 124, a806 (2014).
82. Chinnasamy, D. et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin. Cancer Res. 18, 1672-1683 (2012).
83. Craddock, J. A. et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 33, 780-788 (2010).
84. Karlsson, S. C. et al. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy. Cancer Gene Ther. 20, 386-393 (2013).
85. Pavel, O. et al. Immunomodulatory agent lenalidomide enhances antitumor functions of chimeric receptor-modified t cells in vitro and in vivo [abstract]. Blood 124, a805 (2014).
86. John, L. B. et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19, 5636-5646 (2013).
87. Cruz, C. R. et al. Infusion of donor-derived CD19-redirected-virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase I study [abstract]. Blood 122, a152 (2013).
88. Turtle, C. J. et al. Therapy of B cell malignancies with CD19-specific chimeric antigen receptor-modified T cells of defined subset composition [abstract]. Blood 124, a384 (2014).
89. Derniame, S. et al. Multiplex genome editing as a platform for "off-The-shelf" adoptive CAR T-cell immunotherapies [abstract]. Blood 124, a1111 (2014).
90. Torikai, H. et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-Antigen-receptor and eliminate expression of endogenous TCR. Blood 119, 5697-5705 (2012).
91. June, C. H., Riddell, S. R. & Schumacher, T. N. Adoptive cellular therapy: A race to the finish line. Sci. Transl. Med. 7, 280ps7 (2015).
92. Mack, M., Riethmuller, G. & Kufer, P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl Acad. Sci. USA 92, 7021-7025 (1995).
93. Loffler, A. et al. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95, 2098-2103 (2000).
94. Dreier, T. et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int. J. Cancer 100, 690-697 (2002).
95. Offner, S., Hofmeister, R., Romaniuk, A., Kufer, P. & Baeuerle, P. A. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol. Immunol. 43, 763-771 (2006).
96. Schlereth, B. et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol. Immunother. 55, 503-514 (2006).
97. Kufer, P. et al. Minimal costimulatory requirements for T cell priming and TH1 differentiation: Activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs. Cancer Immun. 1, 10 (2001).
98. Bargou, R. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974-977 (2008).
99. Haas, C. et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 214, 441-453 (2009).
100. Gruen, M., Bommert, K. & Bargou, R. C. T-cell-mediated lysis of B cells induced by a CD19 × CD3 bispecific single-chain antibody is perforin dependent and death receptor independent. Cancer Immunol. Immunother. 53, 625-632 (2004).
101. Klinger, M. et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119, 6226-6233 (2012).
102. Nagorsen, D., Kufer, P., Baeuerle, P. A. & Bargou, R. Blinatumomab: A historical perspective. Pharmacol. Ther. 136, 334-342 (2012).
103. Goebeler, M. E. et al. Final results from a phase 1 study of blinatumomab in patients with relapsed/refractory non-Hodgkin's lymphoma. Hematol. Oncol. 31, 197 (2013).
104. Swerdlow, S. H. et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th edn (International Agency for Research on Cancer, 2008).
105. Topp, M. S. et al. Long-Term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120, 5185-5187 (2012).
106. Topp, M. S. et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29, 2493-2498 (2011).
107. Topp, M. S. et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 32, 4134-4140 (2014).
108. Topp, M. S. et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-Arm, phase 2 study. Lancet Oncol. 16, 57-66 (2015).
109. Viardot, A. et al. Treatment of relapsed/refractory diffuse large B-cell lymphoma with the Bispecific T-cell Engager (BiTE®) antibody construct blinatumomab: primary analysis results from an open-label, phase 2 study [abstract]. Blood 124, a4460 (2014).
110. Zugmaier, G. et al. Long-Term follow-up of serum immunoglobulin levels in blinatumomab-Treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 4, 244 (2014).
111. Goebeler, M. et al. CD3/CD19 bispecific BiTE antibody blinatumomab treatment of non-Hodgkin lymphoma (NHL) patients: 60 μg/m2/d by continuous infusion is tolerable and results in durable responses [abstract 0559]. Haematologica 95 (Suppl. 2), 230 (2010).
112. Viardot, A. et al. Treatment of patients with non-Hodgkin lymphoma (NHL) with CD19/CD3 bispecific antibody blinatumomab (MT103): double-step dose increase to continuous infusion of 60 μg/m2/d is tolerable and highly effective [abstract]. Blood 116, a2880 (2010).
113. Holliger, P., Prospero, T. & Winter, G. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl Acad. Sci. USA 90, 6444-6448 (1993).
114. Moore, P. A. et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 117, 4542-4551 (2011).
115. Kipriyanov, S. M. et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J. Mol. Biol. 293, 41-56 (1999).
116. Brinkmann, U., Reiter, Y., Jung, S. H., Lee, B. & Pastan, I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc. Natl Acad. Sci. USA 90, 7538-7542 (1993).
117. Johnson, S. et al. Effector cell recruitment with novel Fv-based dual-Affinity re-Targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J. Mol. Biol. 399, 436-449 (2010).
118. Rothe, A. et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 125, 4024-4031 (2015).
119. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
120. Dong, H. et al. Tumor-Associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 8, 793-800 (2002).
121. Curiel, T. J. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9, 562-567 (2003).
122. Ruiz-Cabello, F. et al. Phenotypic expression of histocompatibility antigens in human primary tumours and metastases. Clin. Exp. Metastasis 7, 213-226 (1989).
123. Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996).
124. Linsley, P. S. et al. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 4, 535-543 (1996).
125. Linsley, P. S. et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1, 793-801 (1994).
126. Lenschow, D. J. et al. CD28/B7 regulation of TH1 and TH2 subsets in the development of autoimmune diabetes. Immunity 5, 285-293 (1996).
127. Parry, R. V. et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell Biol. 25, 9543-9553 (2005).
128. Latchman, Y. E. et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl Acad. Sci. USA 101, 10691-10696 (2004).
129. Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141-151 (1999).
130. Gotsman, I. et al. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J. Clin. Invest. 117, 2974-2982 (2007).
131. Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985-988 (1995).
132. Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541-547 (1995).
133. Green, M. R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116, 3268-3277 (2010).
134. Chen, B. J. et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-Associated malignancies. Clin. Cancer Res. 19, 3462-3473 (2013).
135. Andorsky, D. J. et al. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-Associated T cells. Clin. Cancer Res. 17, 4232-4244 (2011).
136. Naidoo, J., Page, D. B. & Wolchok, J. D. Immune checkpoint blockade. Hematol. Oncol. Clin. North Am. 28, 585-600 (2014).
137. Green, M. R. et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin. Cancer Res. 18, 1611-1618 (2012).
138. Spranger, S. et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. 5, 200ra116 (2013).
139. Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064-5074 (2014).
140. Steidl, C. et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471, 377-381 (2011).
141. Joos, S. et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res. 60, 549-552 (2000).
142. Berger, R. et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 3044-3051 (2008).
143. Armand, P. et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 31, 4199-4206 (2013).
144. Westin, J. R. et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A single group, open-label, phase 2 trial. Lancet Oncol. 15, 69-77 (2014).
145. Timmerman, J. et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: updated results of a phase I study (CA209-039) [abstract]. Hematol. Oncol. 33, a010 (2015).
146. Garcia-Manero, G. et al. A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies [abstract]. J. Clin. Oncol. 32 (5s Suppl.), TPS3116 (2014).
147. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01953692 (2015).
148. Ansell, S. M. et al. PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311-319 (2015).
149. Armand, P. et al. Nivolumab in patients with relapsed or refractory Hodgkin lymphoma-preliminary safety, efficacy and biomarker results of a phase I study [abstract]. Blood 124, a289 (2014).
150. Moskowitz, C. H. et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013) [abstract]. Blood 124, a290 (2014).
151. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
152. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02220842?term=NCT02220842&rank=1 (2015).
153. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01775631 (2015).
154. Ansell, S. M. et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 15, 6446-6453 (2009).
155. Weber, J. S. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am. Soc. Clin. Oncol. Educ. Book 2012, 174-177 (2012).
156. Weber, J. S., Yang, J. C., Atkins, M. B. & Disis, M. L. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol. 33, 2092-2099 (2015).
157. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
158. Bristol-Myers Squibb Yervoy (ipilimumab): Immune-mediated adverse reaction management guide [online], https://www.hcp.yervoy.com/pdf/rems-management-guide.pdf.
159. Lesokhin, A. M. et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies [abstract]. Blood 124, a291 (2014).
160. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02038946?term=NCT02038946&rank=1 (2015).
161. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02038933?term=NCT02038933&rank=1 (2015).
162. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02181738?term=NCT02181738&rank=1 (2015).
163. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01592370?term=NCT01592370&rank=1 (2015).
164. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
165. Carbognin, L. et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS ONE 10, e0130142 (2015).
166. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014).
167. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
168. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
169. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
170. Reichel, J. et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 125, 1061-1072 (2015).
171. Lin, J. H. et al. Epstein-Barr virus LMP2A suppresses MHC class II expression by regulating the B-cell transcription factors E47 and PU.1. Blood 125, 2228-2238 (2015).
172. Bashey, A. et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 113, 1581-1588 (2009).